Abstract:Background. Lung adenocarcinoma (LUAD) has been recognized as one of the commonest aggressive malignant tumors occurring in humans. The transforming acidic coiled-coil-containing protein 3 (TACC3) seems to be a probable prognostic marker and treatment target for non-small-cell lung cancer (NSCLC). Nevertheless, there exist no reports on the association between TACC3 and immunotherapy or other therapeutic interventions in LUAD. Methods. Premised on the data accessed from The Cancer Genome Atlas- (TCGA-) LUAD, we carried out bioinformatics analysis. The TACC3 expression in LUAD was analyzed utilizing the GEPIA. A survival module was constructed to evaluate the effect of TACC3 on the survival of patients with LUAD. Logistic regression was undertaken to examine the relationship between TACC3 expression and clinical factors. Protein-protein interaction analysis was performed in the GeneMANIA database, and enrichment analysis and identification of predicted signaling pathways were performed using Gene Ontology and Kyoto Encyclopedia of Genes. Additionally, the Cox regression was used to assess the clinicopathologic features linked to the overall survival in TCGA patients. Lastly, we investigated the link between TACC3 and tumor-infiltrating immune cells (TIICs) through CIBERSORT and the "Correlation " module of GEPIA. The association between TACC3 gene expression and drug response was analyzed using the CellMiner database to predict drug sensitivity. Results. The outcomes illustrated that TACC3 was upregulated and considerably correlated with dismal prognosis in LUAD patients. Moreover, the multivariate Cox regression analysis depicted TACC3 as an independent prognostic marker in LUAD patients. It was also revealed that the expression of TACC3 was related to clinical stage (P=0.014), age (P=0.002), and T classification (P <= 0.018). Moreover, we discovered that the expression of TACC3 was considerably linked to a wide range of TIICs, especially the T cells and NK cells. Single-cell results found that TACC3 was mainly expressed in the immune cells (especially tprolif cells) and malignant cells. TACC3 gene expression was positively correlated with TMB and MSI, and TACC3 may provide a prediction of the efficacy of immunotherapy. Moreover, the correlation analysis between TACC3 gene expression and immune checkpoint gene expression revealed that TACC3 may coordinate the activities of these ICP genes in different signal transduction pathways. TACC3 is related to biological progress (BP), cellular component (CC), and molecular function (MF). The pathways involved in the interaction network involving TACC3 include nonhomologous end-joining, RNA transport, pantothenate and CoA biosynthesis, homologous recombination, and nucleotide excision repair. Furthermore, we investigated the association between the expression of TACC3 and the use of antitumor drugs, and TACC3 was positively correlated with response to most drugs. Conclusion. The findings from this research offer robust proof that the expression of TACC3 could be a prognostic marker correlated with TIICs in LUAD. TACC3 can also provide new ideas for immunotherapy as a potential therapeutic target.

High integrin α3 expression is associated with poor prognosis in patients with non-small cell lung cancer

Lung adenocarcinoma-specific three-integrin signature contributes to poor outcomes by metastasis and immune escape pathways

Integrated bioinformatics analysis shows integrin alpha 3 is a prognostic biomarker for pancreatic cancer

Itga3 Is Associated With Immune Cell Infiltration And Serves As A Favorable Prognostic Biomarker For Breast Cancer

Wnt3a Expression Is Associated with Epithelial-Mesenchymal Transition and Impacts Prognosis of Lung Adenocarcinoma Patients.

NPM3 As a Novel Oncogenic Factor and Poor Prognostic Marker Contributes to Cell Proliferation and Migration in Lung Adenocarcinoma

Integrin and gene network analysis reveals that ITGA5 and ITGB1 are prognostic in non-small-cell lung cancer

T Cell Immunoglobulin and Mucin-Domain Containing-3 in Non-Small Cell Lung Cancer

High Expression of ITGA3 Promotes Proliferation and Cell Cycle Progression and Indicates Poor Prognosis in Intrahepatic Cholangiocarcinoma

High Expression of Integrin α3 Predicts Poor Prognosis and Promotes Tumor Metastasis and Angiogenesis by Activating the c-Src/Extracellular Signal-Regulated Protein Kinase/Focal Adhesion Kinase Signaling Pathway in Cervical Cancer

Integrated analysis highlights the significance role of ITGAL in lung adenocarcinoma

High Expression of <i>TACC3</i> Is Associated with the Poor Prognosis and Immune Infiltration in Lung Adenocarcinoma Patients

Immuno-histochemical Expression and Significance of Extracellular Matrix Proteins and Integrin β1 in Non-small Cell Lung Cancer

Low Expression of INHB Co-Receptor TGFBR3 in Connection with Metastasis and Immune Infiltration in Lung Adenocarcinoma.

Integrin αvβ5 as a biomarker for the assessment of non-small cell lung cancer metastasis and overall survival.

ITGAL expression in non-small-cell lung cancer tissue and its association with immune infiltrates

The Prognostic and Immune Infiltration Role of ITGB Superfamily Members in Non-Small Cell Lung Cancer.

Integrin-α7 Expression Positively Correlates with CD44 and CD133 Expressions, and Its High Expression Associates with Advanced Tumor Features As Well As Poor Survivals in Non-Small Cell Lung Cancer Patients

Identification of integrin β1 as a prognostic biomarker for human lung adenocarcinoma using 2D-LC-MS/MS combined with iTRAQ technology.

Expression and Prognostic Analyses of ITGA3, ITGA5, and ITGA6 in Head and Neck Squamous Cell Carcinoma

Expression of Bcl-2, Integrin Α3 Protein in Resected Non-Small Cell Lung Cancer and Its Clinical Relevance